Tenax Therapeutics (NASDAQ:TENX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report sent to investors on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

TENX has been the topic of several other research reports. Leerink Partners set a $20.00 price objective on Tenax Therapeutics in a research report on Monday, March 10th. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Stock Up 2.2 %

Shares of NASDAQ:TENX opened at $6.57 on Friday. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $7.89. The business’s 50 day moving average is $6.44 and its 200 day moving average is $5.35.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in shares of Tenax Therapeutics by 32.4% in the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 5,964 shares during the period. Two Sigma Investments LP bought a new stake in shares of Tenax Therapeutics in the fourth quarter valued at $84,000. Millennium Management LLC bought a new stake in shares of Tenax Therapeutics in the fourth quarter valued at $166,000. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics in the third quarter valued at $101,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Tenax Therapeutics in the third quarter valued at $173,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.